Thousand Oaks, CA, United States of America

Greg Flynn

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Greg Flynn - Innovator in Anti-Sclerostin Antibodies

Introduction

Greg Flynn is a notable inventor based in Thousand Oaks, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of anti-sclerostin antibodies. With a total of 2 patents, Flynn's work is paving the way for advancements in therapeutic treatments.

Latest Patents

Flynn's latest patents include innovative approaches to anti-sclerostin antibodies. The first patent focuses on C-terminal anti-sclerostin antibody variants, which generally relate to antibodies having C-terminal modifications and compositions comprising such antibodies. The second patent also addresses C-terminal antibody variants, emphasizing the same modifications and their potential applications.

Career Highlights

Greg Flynn is currently employed at Amgen Inc., a leading biotechnology company known for its focus on innovative medicines. His work at Amgen has allowed him to collaborate with other talented professionals in the field, enhancing the impact of his inventions.

Collaborations

Some of Flynn's notable coworkers include Zhe Huang and Jennitte LeAnn Stevens. Their collaborative efforts contribute to the ongoing research and development of groundbreaking biotechnological solutions.

Conclusion

Greg Flynn's contributions to the field of anti-sclerostin antibodies exemplify the innovative spirit of modern biotechnology. His patents and work at Amgen Inc. highlight the importance of collaboration and creativity in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…